Background: After the A/H1N1 influenza pandemic in 2009, two new drugs against influenza, namely laninamivir and peramivir, were released in 2010 in Japan. We investigated prescription trends of four neuraminidase inhibitors (NAIs), which are laninamivir, peramivir, oseltamivir, and zanamivir, and assessed clinical data related to influenza for 8 years.
| INTRODUC TI ON
After the A/H1N1 influenza pandemic in 2009, two new drugs against influenza, namely laninamivir and peramivir, were released in 2010 in Japan. Particularly, laninamivir was released only in Japan.
Four neuraminidase inhibitors (NAIs) are typically used after rapid influenza diagnostic tests: oseltamivir (orally administered twice daily for 5 days), zanamivir (inhaled twice daily for 5 days), laninamivir (inhaled just once on the first day), and peramivir (intravenously administered once on the first day or once daily for a maximum of 3 days).
Influenza is one of the most common viral infections affecting global communities annually. During influenza season, doctors typically perform rapid influenza diagnostic tests for patients with sudden-onset high fever. If tested positive, NAIs can be prescribed to patients, even to those with no risk factors. Meta-analyses of 2009 influenza pandemic showed that early NAI treatment versus late was associated with a significant reduction in mortality. 1 Sugaya N. et al also showed early treatment with NAIs led to very low mortality rate in children during the 2009 influenza pandemic in Japan. 2 Patients diagnosed with influenza are prescribed NAIs in outpatient clinics, after which they rarely revisit the hospital or clinic. Therefore, it is difficult for doctors to know the treatment outcomes of these patients. During the winter season, doctors are too busy to investigate detailed treatment outcomes owing to the volume of patients with viral infections, cardiovascular diseases, or respiratory diseases. Therefore, we conducted a less time-intensive self-reported survey using a postcard questionnaire. This method poses a lower burden for doctors and for patients with influenza previously treated with NAIs. [3] [4] [5] [6] To investigate the status of patients with influenza and their medication use, we distributed postcard survey questionnaires to patients in Osaka Prefecture from the 2010-2011 winter season.
During 2010-2011 season, laninamivir appeared to alleviate fever faster, with fewer adverse events. 3 During 2011-2012 season, laninamivir was prescribed more often than during the previous season and the four NAIs had similar fever-alleviating effects. 4 Furthermore, we had reported that during the 2012-2013 and 2013-2014 seasons, fever in patients with type A influenza was alleviated earlier than those with type B influenza. 5, 6 This descriptive epidemiologic study was performed to reveal three points. (a) Difference of each NAI's effects: We report prescription trends of four NAIs and time course of fever in patients after taking these inhibitors; (b) difference between influenza type; and (c) difference of fever in patients of influenza by ages. We present data of eight seasons.
| MATERIAL S AND ME THODS
This study is observational, cross-sectional study of influenza for eight years. This study was conducted in 72 hospitals or clinics in Osaka Prefecture, and some institutions were changed by the season. In the first year of this survey, we recruited institutions which are recommended by department of respiratory medicine, pediatric medicine, and otolaryngology of Osaka City University.
As of hospitals, specialists of internal medicine, pediatric medicine, and otolaryngology were in charge of this survey. Each clinic was in charge of 10-30 postcards, depending on their institutional capacity. Overall, 833-1050 postcards were prepared for distribution by clinics. Inclusion criteria were that patients were diagnosed using rapid influenza diagnostic tests, and NAIs were Cases with missing data on age, sex, influenza type, or prescribed NAIs were excluded.
We defined the duration of fever as the time from NAI administration until the patients became afebrile. Fever reduction was defined as temperatures < 37.5°C in patients aged < 10 years or < 37.0°C in those aged ≥ 10 years, as previously described. 7, 8 This study was ap- 
| Statistical analysis
Statistical analyses were performed with JMP (version 10; SAS Institute, Inc). Mann-Whitney test was performed to compare the proportion of NAIs between two age groups of type A influenza.
A log-rank test was used to compare about fever alleviation among NAIs or influenza type. A Fisher's exact test was used to compare the proportion of highest fever among age groups. For all statistical analysis, P values of <.05 were considered significant.
| RE SULTS
Characteristics of this survey are displayed in Table 1 2). As seen in Figure 2C , only around 20 patients were diagnosed with type B influenza during each season. Zanamivir was prescribed to approximately 20% of patients with type B influenza. This NAI was preferred for use in patients with type B influenza compared to those with type A.
| Laninamivir was most prescribed to patients aged ≥ 10 years, and oseltamivir was most prescribed to those aged < 10 years

| All NAIs had similar effects on influenza
The time until fever alleviation did not differ according to the NAI used except the 2016-2017 season. Figure 3A shows representative results from the 2014-2015 season to 2017-2018 season. The data before 2013-2014 season were already reported in previous papers. [3] [4] [5] [6] Most seasons had the same results about the effects of NAIs for alleviation of fever.
| Patients with type A influenza achieved fever alleviation earlier than those with type B influenza
The time until fever alleviation was compared between patients with type A influenza and those with type B influenza during the 2015-2016 season and 2017-2018 season ( Figure 3B ). We did not show the data of 2014-2015 and 2016-2017 season because of small number of influenza type B patients. The data before 2013-2014 season were already reported in previous papers, and they were mostly the same results. [3] [4] [5] [6] Patients with type A virus achieved fever alleviation significantly earlier. We did not show the data before 2013-2014 season because they were already published. [3] [4] [5] [6] The number of patients with fever ≥39°C gradually decreased and that of patients with fever <38°C gradually increased with age (P < .0001). Thus, older patients with influenza may not uniformly exhibit high fever. Peramivir should be infused via an intravenous drip for more than 15 minutes. Therefore, peramivir was prescribed to few patients to prevent the spread of influenza in clinics or hospitals during long hospital stays. Oseltamivir and zanamivir were administered for longer durations than laninamivir and peramivir. Importantly, patients need to complete five full days of these drugs and not discontinue early or when they begin to feel better. The National Institute of Infectious
| Older patients had significantly lower fever
| D ISCUSS I ON
Diseases of Japan has reported that anti-influenza drug resistance was rarely observed during 8 years, 9 Although this postcard survey was relatively easy to conduct and produced results with a low burden for doctors and patients, three limitations exist. The first limitation is bias of doctors and patients.
Doctors' biases involve a prescription bias and a selection bias.
Doctors deciding which NAI to prescribe could produce a prescription bias, which is influenced by prescribers' belief, drug access, or other social factors. We had previously reported that there were no significant differences in sex, age distribution, or choice of prescribed drugs between our survey and the Japan Physicians Association report, which is one of the most reliable investigations of influenza in Japan. [3] [4] [5] [6] 10 These results may reflect that all patients did not measure fever twice a day. The Ministry of Health, Labour and Welfare had provided the number of prescriptions of NAIs in 2012-2013 based on data furnished by pharmaceutical companies. 18 These data showed the proportions of prescribed NAIs to be 45% 14%, 39%, and 2% for oseltamivir, zanamivir, laninamivir, and peramivir, respectively. These proportions are similar to our findings: 45% oseltamivir, 12% zanamivir, 39% laninamivir, and 4% peramivir. Therefore, our survey population might be representative supporting the reliability of our data.
The third limitation is not to show a comparison between patients with NAIs and without NAIs. It is not possible to verify whether NAI is effective compared to nonuse.
It is very important for them to know the current status of the four NAIs. This study supported NAIs had mostly the same effect and better to alleviate fever in type A influenza patients than type B, or elderly patients did not have high fever in influenza infection.
In conclusion, our descriptive epidemiologic study about influenza patients for eight years revealed the status on patients of influenza and their medication use. 
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